ABVC BioPharma completes Phase II Part 2 study site initiation visit at UCSF

ABVC BioPharma announced that the site initiation visits at the University of California San Francisco Medical Center, UCSF, was conducted on March 29, 2023. The UCSF site, led by Professor Keith McBurnett, PhD, at the UCSF Weill Institute for Neurosciences, will join five other Taiwan sites for ABVC BioPharma’s Phase II Part 2 clinical study in patients with ADHD. "We are pleased to have Professor Keith McBurnett leading the UCSF team to perform ADHD Phase II Part 2 study," said Dr. Howard Doong, ABVC BioPharma’s Chief Executive Officer. "The quality and fast-moving enrollment at the UCSF site will help complete the study in a timely manner." Further, Dr. Doong emphasized the importance of ABVC BioPharma’s focus on botanical sourcing in drug development. "Our clinical trials continue to demonstrate that medicines derived from plants have significant therapeutic benefits with few – if any – side effects in treating serious medical conditions."